Zydus Cadila has said that the patent litigation relating to Allergan’s Delzicol, that is used in treating uclerative colitis, has been settled.
Zydus Cadila has said in a statement that the patent litigation relating to Allergan’s Delzicol (mesalamine) has been settled.
It added that “As a result of the settlement, and if approved by FDA, its US subsidiary, Zydus Pharmaceuticals (USA) Inc, will be able to market its generic version of Delzicol in the US beginning on March 1, 2020, or earlier under certain circumstances.”
